Detect Decode Decide
What is Nautilus BrainPulse?
The Jan Medical Nautilus BrainPulse™ is the first portable brain-sensing system designed to rapidly diagnose cerebral disorders. The device emits zero energy into the brain and relies on passive sensors that are completely non-invasive. A single patient recording is simple to conduct and will take less than one minute from start to finish. Unlike most imaging modalities that take "snapshots” in time, BrainPulse will have the capability of continually monitoring the brain’s pulse.
The brain has a normal pulse driven by the cardiac cycle. The impact of this pulse on the skull can be detected and measured by digitizing the signal patterns from sensors measuring the skull’s motion, and extracting features (signatures) from them. Algorithms can then be developed to identify normal - and a variety of abnormal - brain pulse patterns.
Most brain pathologies, whether structural (dementia, solid tumors, aneurysm, hemorrhage and hydrocephalous) or vascular (vasospasm, ICP, ischemic stroke and AVMs) physically alter the brain’s pulse. Jan Medical, with BrainPulse, intends to develop and commercialize algorithms that can identify the wide variety of brain pulse patterns, particular to these and other cerebral abnormalities.
Many major brain pathologies including trauma, neuro-degenerative disease, aneurysm and stroke cannot be adequately diagnosed with exclusive reliance on imaging technologies. In concussion, dementia and hydrocephalous, imaging does not yet provide a reliable diagnosis. CT and advanced imaging rarely detect ischemic stroke within the limited therapeutic window required for optimal treatment. For ICP, shunt management and aneurysm tracking, imaging and monitoring technology is too invasive to encourage routine utilization. Beyond these limitations, imaging studies are expensive, require specialized personnel and are time consuming. A non-invasive aid to diagnosis that is able to measure brain structure/physiology in near real-time will accelerate and expand access to critical information, shorten the path to treatment and improve the diagnostic experience.
Patients surviving and recovering from ruptured cerebral aneurysms have a 30-40% chance of suffering a symptomatic cerebral vasospasm within three weeks of the initial rupture. In anticipation, patients are admitted to the NCCU for an average 14 days of observation. Monitoring of these patients is accomplished currently with trans-cranial Doppler (TCD). TCD is not used to continually monitor a patient; monitoring frequency becomes more pronounced with the onset of spasm and remains throughout the prolonged episode. TCD however is neither sensitive (60%) nor specific (90%) to spasm. The lack of specificity can result in an unnecessary CTA or significantly, more involved and expensive digital subtraction angiography (DSA). Additionally, TCD is highly operator dependent, not universally applicable, and practically limited to the hours of the day when ultrasonographers are present. Jan Medical has studied these limitations and developed a product that will be more sensitive, specific and timely in identifying the early signs of spasm and will monitor the spasm episode more constantly and accurately.
Concussion is an everyday concern for athletes in most contact sports including football, rugby, hockey, basketball, soccer, boxing and lacrosse. International studies of the rate of concussions in sports range from one to up to nine per 1000 player hours, depending on activity and level of play. Potentially lethal second concussions, known as Second Impact Syndrome (SIS), can occur during recovery from an initial concussion. While cognitive tests are generally effective at diagnosing an initial concussion, they do not provide the assurance of a physiologic test in terms of grading the severity of the injury or, more significantly, in making return to play determinations. The expectation is that BrainPulse will have the capability of identifying not only an initial concussion, but crucially to also track the course of recovery and return to normal.
Jan Medical is engaged in ongoing discussions with investigators in the US, Europe, Asia and Australasia who have expressed interest in developing algorithms for normal pressure hydrocephalous, brain tumors, Parkinson’s disease, and in building on our earlier experience with aneurysm and ischemia. We expect the Nautilus BrainPulse 1000 will advance efforts worldwide in decoding the brain’s pulse and may one day lead to exciting advances in identifying, understanding and monitoring a wide variety of cerebral pathologies.
Jan Medical currently has completed and is conducting clinical studies at John Hopkins, Stanford University, The University of California, San Francisco (UCSF) and Universitätsklinikum Mainz.
To learn more about current studies or for more information on how to become involved, contact email@example.com.